|
1
|
Chung CH, Parker JS, Karaca G, Wu J,
Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X,
et al: Molecular classification of head and neck squamous cell
carcinomas using patterns of gene expression. Cancer Cell.
5:489–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zvrko E, Mikic A and Vuckovic L:
Clinicopathologic significance of CD105-assessed microvessel
density in glottic laryngeal squamous cell carcinoma. Auris Nasus
Larynx. 37:77–83. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gooi Z, Richmon J, Agrawal N, Blair E,
Portugal L, Vokes E, Seiwert T, de Souza J, Saloura V, Haraf D, et
al: AHNS Series- Do you know your guidelines? Principles of
treatment for nasopharyngeal cancer: A review of the National
Comprehensive Cancer Network guidelines. Head Neck. 39:201–205.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kotwall C, Sako K, Razack MS, Rao U,
Bakamjian V and Shedd DP: Metastatic patterns in squamous cell
cancer of the head and neck. Am J Surg. 154:439–442. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Milisavljevic D, Stankovic M, Zivic M,
Popovic M and Radovanović Z: Factors affecting results of treatment
of Hypopharyngeal Carcinoma. Hippokratia. 13:154–160.
2009.PubMed/NCBI
|
|
6
|
Chu PY, Wang LW and Chang SY: Surgical
treatment of squamous cell carcinoma of the hypopharynx: Analysis
of treatment results, failure patterns, and prognostic factors. J
Laryngol Otol. 118:443–449. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu PY and Chang SY: Reconstruction of the
hypopharynx after surgical treatment of squamous cell carcinoma. J
Chin Med Assoc. 72:351–355. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim J, Chu J, Shen X, Wang J and Orkin SH:
An extended transcriptional network for pluripotency of embryonic
stem cells. Cell. 132:1049–1061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weidgang CE, Russell R, Tata PR, Kühl SJ,
Illing A, Müller M, Lin Q, Brunner C, Boeckers TM, Bauer K, et al:
TBX3 directs cell-fate decision toward mesendoderm. Stem Cell
Reports. 1:248–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Russell R, Ilg M, Lin Q, Wu G, Lechel A,
Bergmann W, Eiseler T, Linta L, Kumar PP, Klingenstein M, et al: A
dynamic role of TBX3 in the pluripotency circuitry. Stem Cell
Reports. 5:1155–1170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan W, Huang X, Chen C, Gray J and Huang
T: TBX3 and its isoform TBX3+2a are functionally distinctive in
inhibition of senescence and are overexpressed in a subset of
breast cancer cell lines. Cancer Res. 64:5132–5139. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miao ZF, Liu XY, Xu HM, Wang ZN, Zhao TT,
Song YX, Xing YN, Huang JY, Zhang JY, Xu H and Xu YY: Tbx3
overexpression in human gastric cancer is correlated with advanced
tumor stage and nodal status and promotes cancer cell growth and
invasion. Virchows Arch. 469:505–513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shan ZZ, Yan XB, Yan LL, Tian Y, Meng QC,
Qiu WW, Zhang Z and Jin ZM: Overexpression of Tbx3 is correlated
with Epithelial-Mesenchymal Transition phenotype and predicts poor
prognosis of colorectal cancer. Am J Cancer Res. 5:344–353.
2014.PubMed/NCBI
|
|
14
|
Beukers W, Kandimalla R, Masius RG,
Vermeij M, Kranse R, van Leenders GJ and Zwarthoff EC:
Stratification based on methylation of TBX2 and TBX3 into three
molecular grades predicts progression in patients with pTa-bladder
cancer. Mod Pathol. 28:515–522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burgucu D, Guney K, Sahinturk D, Ozbudak
IH, Ozel D, Ozbilim G and Yavuzer U: Tbx3 represses PTEN and is
over-expressed in head and neck squamous cell carcinoma. BMC
Cancer. 12:4812012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peres J, Davis E, Mowla S, Bennett DC, Li
JA, Wansleben S and Prince S: The highly homologous T-box
transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Willmer T, Hare S, Peres J and Prince S:
The T-box transcription factor TBX3 drives proliferation by direct
repression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cell
Div. 11:62016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cioffi M, Trabulo SM, Sanchez-Ripoll Y,
Miranda-Lorenzo I, Lonardo E, Dorado J, Reis Vieira C, Ramirez JC,
Hidalgo M, Aicher A, et al: The miR-17–92 cluster counteracts
quiescence and chemoresistance in a distinct subpopulation of
pancreatic cancer stem cells. Gut. 64:1936–1948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amir S, Simion C, Umeh-Garcia M, Krig S,
Moss T, Carraway KL III and Sweeney C: Regulation of the T-box
transcription factor Tbx3 by the tumor suppressor microRNA-206 in
breast cancer. Br J Cancer. 114:1125–1134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jang JY, Kim EH, Cho J, Jung JH, Oh D, Ahn
YC, Son YI and Jeong HS: Comparison of oncological and functional
outcomes between initial surgical versus non-surgical treatments
for hypopharyngeal cancer. Ann Surg Oncol. 23:2054–2061. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kleszcz R, Paluszczak J, Krajka-Kuźniak V
and Baer-Dubowska W: The inhibition of c-MYC transcription factor
modulates the expression of glycolytic and glutaminolytic enzymes
in FaDu hypopharyngeal carcinoma cells. Adv Clin Exp Med.
27:735–742. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu CM, Lin PM, Tsai YT, Tsai MS, Tseng
CH, Lin SF and Yang MY: NVP-BEZ235, a dual PI3K-mTOR inhibitor,
suppresses the growth of FaDu hypopharyngeal squamous cell
carcinoma and has a synergistic effect with Cisplatin. Cell Death
Discov. 4:572018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu J, Lei DP, Jin T, Zhao XN, Li G and
Pan XL: Altered expression of miR-21 and PTEN in human laryngeal
and hypopharyngeal squamous cell carcinomas. Asian Pac J Cancer
Prev. 12:2653–2657. 2011.PubMed/NCBI
|
|
26
|
Washkowitz AJ, Gavrilov S, Begum S and
Papaioannou VE: Diverse functional networks of Tbx3 in development
and disease. Wiley Interdiscip Rev Syst Biol Med. 4:273–283. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Renard CA, Labalette C, Armengol C, Cougot
D, Wei Y, Cairo S, Pineau P, Neuveut C, de Reyniès A, Dejean A, et
al: Tbx3 is a downstream target of the Wnt/beta-catenin pathway and
a critical mediator of beta-catenin survival functions in liver
cancer. Cancer Res. 67:901–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peres J, Mowla S and Prince S: The T-box
transcription factor, TBX3, is a key substrate of AKT3 in
melanomagenesis. Oncotarget. 6:1821–1833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng X, Yao W, Zhang Z, Yuan F, Liang L,
Zhou J, Liu S and Song J: T-box transcription factor Tbx3
contributes to human hepatocellular carcinoma cell migration and
invasion by repressing E-cadherin expression. Oncol Res.
26:959–966. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du HF, Ou LP, Yang X, Song XD, Fan YR, Tan
B, Luo CL and Wu XH: A new PKCα/β/TBX3/E-cadherin pathway is
involved in PLCε-regulated invasion and migration in human bladder
cancer cells. Cell Signal. 26:580–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim CH, Kim J, Kahng H and Choi EC: Change
of E-cadherin by hepatocyte growth factor and effects on the
prognosis of hypopharyngeal carcinoma. Ann Surg Oncol.
14:1565–1574. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Willmer T, Peres J, Mowla S, Abrahams A
and Prince S: The T-Box factor TBX3 is important in S-phase and is
regulated by c-Myc and cyclin A-CDK2. Cell Cycle. 14:3173–3183.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
García-Reyes B, Kretz AL, Ruff JP, von
Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D and Lemke
J: The emerging role of cyclin-dependent kinases (CDKs) in
pancreatic ductal adenocarcinoma. Int J Mol Sci. 19:2018.
View Article : Google Scholar
|
|
34
|
Xiao W, Jiang Y, Men Q, Yuan L, Huang Z,
Liu T, Li W and Liu X: Tetrandrine induces G1/S cell cycle arrest
through the ROS/Akt pathway in EOMA cells and inhibits angiogenesis
in vivo. Int J Oncol. 46:360–368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Swaffer MP, Jones AW, Flynn HR, Snijders
AP and Nurse P: CDK substrate phosphorylation and ordering the cell
cycle. Cell. 167:1750.e16–1761.e16. 2016. View Article : Google Scholar
|
|
36
|
Galea CA, Nourse A, Wang Y, Sivakolundu
SG, Heller WT and Kriwacki RW: Role of intrinsic flexibility in
signal transduction mediated by the cell cycle regulator, p27 Kip1.
J Mol Biol. 376:827–838. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carlson H, Ota S, Song Y, Chen Y and
Hurlin PJ: Tbx3 impinges on the p53 pathway to suppress apoptosis,
facilitate cell transformation and block myogenic differentiation.
Oncogene. 21:3827–3835. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wensing LA and Campos AH: TBX3, a
downstream target of TGF-β1, inhibits mesangial cell apoptosis. Exp
Cell Res. 328:340–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Warren CFA, Wong-Brown MW and Bowden NA:
BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis.
10:1772019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brown JM and Attardi LD: The role of
apoptosis in cancer development and treatment response. Nat Rev
Cancer. 5:231–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li X, Ruan X, Zhang P, Yu Y, Gao M, Yuan
S, Zhao Z, Yang J and Zhao L: TBX3 promotes proliferation of
papillary thyroid carcinoma cells through facilitating
PRC2-mediated p57KIP2 repression. Oncogene.
37:2773–2792. 2018. View Article : Google Scholar : PubMed/NCBI
|
